The short version.
The bioavailability problem is real: oral glutathione is mostly degraded by gastric and intestinal proteases before it reaches systemic circulation. That's why clinical protocols typically use IV or subq routes when the goal is a meaningful systemic increase.
IV produces a fast, large rise in plasma glutathione during infusion. Subq is slower, with a lower peak and a more distributed exposure. The choice between them is less about "which works better" and more about what the use case looks like — episodic clinical use, ongoing maintenance, or part of a layered protocol.
| Topic | IV glutathione | Subq glutathione |
|---|---|---|
| Onset / peak | Direct circulation, high peak during infusion | Slower absorption, lower peak |
| Session length | Typically 30-60 minutes in clinic | Minutes, self-administered |
| Tolerability | Sulfurous taste/smell common; rare hypersensitivity | Generally well-tolerated; possible injection-site irritation |
| Practical friction | Clinic-based; clinical supervision | Home subq workflow |
| Best fit | Periodic / supervised dosing | Routine, ongoing use |
Pharmacokinetics, tolerability, friction.
IV. Direct delivery into circulation produces the highest peak. Side effects in IV glutathione are typically mild — a sulfur-like taste or smell during infusion is common. Rare hypersensitivity reactions have been reported, and FDA has flagged safety concerns specifically with high-dose injectable glutathione marketed for cosmetic skin lightening — that's a different setting from carefully-supervised clinical use.
Subq. Subcutaneous injection produces a slower, lower-peak rise but is convenient and amenable to a maintenance schedule. Standard subq workflow applies — clean technique, site rotation, sterile compounding from a 503A pharmacy.
Most people on a maintenance protocol use subq because the schedule and home workflow fit better. Periodic IV makes sense in supervised settings or when paired with a specific clinical context. As with NAD+, plenty of people use both — periodic IV plus subq in between.
Oral doesn't really get there. IV and subq do — but for different schedules and use cases.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Given my goals, does IV every few weeks plus subq maintenance make sense?
- If I have asthma or sulfite sensitivity, are there contraindications I should know?
- How will we monitor — labs, symptoms, both?
- What's a sensible trial period before reassessing?
- What sterile-handling and storage practices matter at home?
Sources